Aspergillus fumigatus (AF) is a ubiquitous mold and is the most common cause of invasive aspergillosis, an important source of morbidity and mortality in immunocompromised hosts.
Introduction
Aspergillus fumigatus (AF) is the most common cause of invasive aspergillosis (IA) and a major source of infection-related mortality in immunocompromised patients, such as allogeneic stem cell transplant (SCT) recipients 1, 2 . In these patients prophylactic antifungal therapy has been found to have little effect on disease incidence 1, [3] [4] [5] . Despite advances in early diagnosis and new antifungal agents 3, 6, 7 , IA remains a leading cause of death in this patient population with an attributable mortality rate ranging from 30 to 80% 8 . AF is among the most ubiquitous of those fungi with airborne conidia (spores), and is commonly found in human domiciles. Pulmonary infection by AF, the predominant type of IA, is acquired through the inhalation of Aspergillus conidia, while the invasion stage of the disease is characterized by hyphal destruction of pulmonary tissue 1 . The mediocre efficacy of antifungals in the setting of profound immunosuppression contributes to the poor prognosis of this opportunistic infection. The development of effective strategies to improve AFspecific immune reconstitution should greatly influence the natural history of IA.
Historically, there was a biphasic distribution of IA following BMT; IA was most common in the pre-engraftment period associated with neutropenia, with a second peak in incidence associated with acute and/or chronic graft versus host disease (GVHD) 5 . However, recent reports have indicated late-onset IA predominates after allogeneic SCT, often in concomitance with the occurrence of GVHD and corticosteroid administration 9, 10 when patients are not neutropenic 3, 6, 7 . It has been shown that lymphopenia may also function as a risk factor during the late post-transplant period. The protective role for T cells is supported by increased risk of IA associated with T-cell depletion or CD34 selection 6 . These studies provided evidence that the adoptive transfer of T cells may be important in protection from disease in recipients 11 .
Because AF is a ubiquitous environmental fungus, it seems likely that healthy subjects would have detectable AF-specific T cells within peripheral blood mononuclear cells (PBMC).
Recently, it has been reported by Hebart et al. 12 that it is possible to detect AF-specific T cell activation in healthy individuals in response to AF cellular extracts with a predominant release of interferon-γ (IFNγ) in culture supernatants, indicating a TH1 response. Patients
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As is the case with other fungi, AF produces a number of toxins. The most abundant mycotoxin produced by AF is gliotoxin (GT), a hydrophobic metabolite that belongs to the class of epipolythiodioxopiperazine (ETP) compounds, characterized by the presence of a quinoid moiety and disulfide bridge across the piperazine ring 5, 15 . GT exhibits diverse biological activities on the immune system. In murine models of IA, GT was shown to inhibit macrophage and polymorphonuclear cell function, including phagocytosis and bactericidal activity [16] [17] [18] . Further, GT was shown to block the generation of alloreactive cytotoxic T lymphocytes 19 . It has been shown that GT specifically inhibits the nuclear transcription factor NF-κB, a central regulator of the immune response, preventing the NF-κB-induced transcription of various inflammatory cytokines, hematopoietic growth factors, growth factor receptors and cell adhesion molecules 20 .
The immunosuppressive properties of GT, in conjunction with the fact that the mycotoxin is released only by the hyphal form of AF 21 , suggest that the in situ production of GT by AF might play an important role in the pathogenesis of IA. Because of its known effects on lymphocytes, GT has been considered for immunosuppressive therapy in bone marrow 22 and solid organ transplantation 23 . Recently, we demonstrated that high levels of circulating GT (e.g., >100 ng/ml) were detectable in serum specimens obtained from a majority of patients with documented IA, and only occasionally detectable in similar patients at risk for IA but without evidence of disease 24 .
In this study we show that CD4+ and CD8+ T cells in healthy donors demonstrate only weak functional responses to AF crude filtrates by cytokine flow cytometry (CFC), and that AF may actively suppress the T cell response to viral pathogens and mitogens via production of GT. In addition, we sought to determine the mechanism by which GT inhibits T cell responses. We demonstrated that GT acts primarily by targeting and killing antigen presenting cells (e.g., monocytes and dendritic cells) resulting in impaired antigen presentation. We also found, in vitro, that this effect on peripheral blood antigen-presenting 
Assessment of T cell function by cytokine flow cytometry (CFC).
Functional T cell responses were assessed by CFC as previously described 25, 26 Assessment of apoptosis using a caspase-3 induction assay. Mature DC (mDC) were permeabilized and stained with FITC-conjugated CD83 and PEconjugated active caspase-3. mDC were then analyzed by flow cytometry by sequential gating on DC using scatter and CD83 expression, and then on active caspase-3+ cells.
Statistical Methods
Statistical analyses were performed using Prism statistical software (GraphPad Software, San Diego, CA). Intergroup comparisons were performed using the Mann-Whitney U test (for univariate nonparametric group analyses). All P values were 2-tailed and considered Similarly, we failed to detect cytokine production in AF-stimulated CD8+ T cells (not shown). Given the ubiquity of AF as an environmental pathogen, these data suggested that human subjects were unable to sustain frequencies of AF-specific T cells similar to those recognizing endogenous herpesviruses. Based on the potential immunosuppressive properties of gliotoxin 17, 18 , we hypothesized that mycotoxin-mediated immune suppression might have contributed to our observed results.
GT inhibits human T cell function in a dose-dependent manner.
We tested the capacity of GT to suppress functional CD4+ and CD8+ T cell responses to known antigens, including SEB and CMV preparations. We found a dose-dependent reduction in the frequency of cytokine-producing SEB-and CMV-stimulated T cells when GT was added to the culture. As evidenced by a typical subject ( Fig. 2A) , the SEB response in the absence of GT was 12.3%, while the addition of GT, even at a low concentration of 100 ng/ml, resulted in a diminished response of only 2.7% in the CD4+ cells. The response decreased further to 1.2% when the concentration of GT was increased to 200ng/ml. Figures 2B and 2C display the composite results from five healthy donors. Cells were stimulated with SEB and then incubated with GT at the specified concentrations. At minimal concentrations (50ng/ml) the responses declined by approximately 50% in both the CD4+ and CD8+ T cell compartments. This decline continued in both populations until a near-complete disappearance of specific responses was noted with doses ≥ 300 ng/ml for CD4+ T cells and ≥ 400 ng/ml for CD8+ T cells. These concentrations are below those typically found in crude AF lysates, and approximate those found in serum in patients with IA 24 . Figure 2D depicts concordant suppression of T cell activation in both CD4+ and CD8+ T cell subsets in a representative experiment, irrespective of whether IFNγ or TNFα production was assessed as an endpoint in the CFC assay. Comparable suppression was seen following stimulation with CMV antigens in CD4+ and CD8+ T cells, in experiments assessing both IFNγ and TNFα production (data not shown).
GT induces preferential death of monocytes.
Additional studies demonstrated that incubation with GT resulted in a substantial decrease in the frequency of viable monocytes during the stimulation period but no significant decrease in the frequency of lymphocytes (Fig. 3) . Following incubation with GT, the percentage of cells within the monocytoid gate was just 1.24% while those within the lymphoid gate represented 47.4% of the total cell population (Fig. 3A) . In contrast, in the absence of GT approximately 16.2% of cells fell within a monocyte gate while 49.8% of cells had scatter properties consistent with lymphocytes (Fig. 3B) . Incubation of PBMC with crude filtrates of AF hyphae also caused a considerable decrease in the number of viable monocytes, assessed by scatter, just as seen with incubation with GT, though the presence of GT could not be confirmed within the crude filtrates. While the lymphocyte fraction was reduced slightly from 28.6% to 20.3% after incubation with an AF lysate, the monocyte fraction was reduced substantially from 11.4% to 2.4% (Fig. 3C ). This reduction in the monocyte fraction led to a skewing in the number of lymphocytes compared to monocytes with the ratio (lymphocytes:monocytes) becoming greater with increasing doses of GT (Fig. 3E) . PBMC cultured without GT contained a ratio of lymphocytes to monocytes of 2.8:1; in PBMC incubated with GT at 150 ng/ml this ratio increased to 13:1 while incubation with GT at 300 ng/ml resulted in a ratio of 42:1. Linear regression analysis (not shown) revealed a positive correlation between increasing GT concentration and higher lymphocyte:monocyte ratio (r 2 =0.91, p<0.001). Taken together, these results suggest that GT induces preferential death of monocytes in vitro, leading to marked decreases in the ratio of monocytes to lymphocytes.
GT inhibits T cell activation primarily by inhibiting antigen presentation.
Next, we tested the capacity of GT to target the function of antigen-presenting cells (APC) in vitro. In the typical cytokine flow cytometry (CFC) assay of T cell function, PBMC are stimulated with antigens for six hrs, with brefeldin A added to block cytokine export for the last five hrs of the incubation period. The addition of brefeldin A, which is necessary to facilitate the detection of cytokines in activated T cells, is delayed to allow antigen presentation to occur during the first hour of incubation with antigens.
Addition of GT during the first hour of culture, when the majority of antigenpresentation takes place, resulted in greater inhibition of functional T cell responses than when GT was added during the last five hrs of the six hr stimulation (Fig. 4) . Cells were stimulated with SEB or CMV, and either GT was added at time zero (and washed at 1 hr prior to addition of brefeldin A) or after 1 hr of incubation with the antigens. In the experiments in which GT was present during the first hour of stimulation, the frequencies of T cells activated following stimulation with viral antigens or superantigens declined significantly (e.g., the frequency of CD4+CD69+TNFα+ T cells declined to 0.64% following SEB stimulation and 0.27% after CMV stimulation, similar to background levels). CD4+ T cell responses were only moderately suppressed when GT was added after the initial hour of stimulation with SEB and CMV, 10.5% and 0.91%, respectively compared to 13.9% and 1.86% in the absence of GT. Neither of these represented significant differences between the pairs (p=0.19 for SEB and p=0.09 for CMV). Responses within the CD8+ cells followed the same pattern. The addition of GT during the first hour resulted in a significantly reduced response to SEB and CMV (0.53% and 0.26%, respectively) while addition of GT after the first hour was associated with near normal functional responses, 4.2% with SEB and 1.03% with CMV. Thus, the presence of GT in the crucial interval during which antigen presentation primarily occurs led
to a marked decrease in T cell activation. These results support the hypothesis that GT exerts its primary immunosuppressive effects via impairment of antigen presentation, rather than the direct inhibition of lymphocyte function.
GT-induces monocyte death via apoptosis.
We sought to determine whether monocyte death induced by GT occurred via apoptosis (Fig. 5) . To assess apoptosis induction by GT in monocytes, T cells and B cells, PBMC were either incubated with or without 35 ng/ml of GT and the induction of caspase-3, a terminal effector of apoptotic cell death, was assessed using a flow cytometric assay (Fig. 5) . A typical example of caspase-3 expression in monocytes is shown in Fig. 5A . Monocytes express very little active caspase-3 when incubated in media alone; after 3 hrs the percent of caspase-3 positive monocytes was still very low at 1.13%. In those monocytes that were incubated with GT, a relatively high percentage of cells were caspase-3 positive after just 2 hrs, 6.1%, and an even larger proportion, 27.4%, were positive after 3 hrs.
The composite results of 7 experiments are shown in Fig. 5B . Caspase-3 induction was assessed in CD14+ monocytes, CD4+ and CD8+ T cells, and in CD19+ B cell fractions. In the absence of GT, the percentages of caspase-3 positive cells were low in all populations, never reaching 5% even after 6 hrs of incubation. In contrast, cells incubated with GT show a marked increase in caspase-3 positivity over the time course. Although this increase occurred to some extent in all cell types, apoptosis was preferentially seen in monocytes. After just 3 hrs, the monocyte fraction contains approximately 20% caspase-3 positive cells, and after 6 hrs this number rises to almost 60% and most monocytes in the incubated culture are dead or dying. In the three lymphocyte subsets CD4+, CD8+ and CD19+ cells, we observed much lower caspase-3 positive cell fractions of 1.9%, 1.8%, and 6.6% after 3 hrs, respectively; and 7.1%, 25.5%, and 18.7% after 6 hrs, respectively. These data demonstrated that the preferential destruction of monocytes was due to the induction of apoptosis by GT.
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Confirmation of monocyte apoptosis using Annexin V staining.
We sought to confirm our finding that GT induces apoptosis preferentially in monocytes in an Annexin V assay of apoptosis. To eliminate the possibility of bystander effects, CD14+
and CD14-populations were separated using positive and negative selection using magnetic bead separation, prior to incubation with GT and assessment of Annexin V staining by flow cytometry. Annexin V positivity represents a very early stage in the apoptotic pathway.
Both CD14+ PBMC subsets (monocytes) and CD14-cells (lymphocytes) were co-cultured in the presence of 35 ng/ml GT for 1 to 6 hrs. The percentage of Annexin-positive apoptotic cells increased during the incubation time in both cell populations, although the predominant effect of the mycotoxin was again seen in monocytes (Fig. 6 ). The percentage of monocytes undergoing apoptosis as judged by annexin V and PI staining was 6.4% after 1 hr and 50.4% after 6 hrs. As noted above, apoptosis was also induced by GT in lymphocytes, but to a much lesser extent (from an average apoptotic fraction of 2.2% after 1 hr to 20.3% after 6 hrs).
Apoptosis induction in monocytes was significantly higher than that observed in lymphocytes (p <0.003). The controls showed a consistently low level of apoptosis during the time course (≤1.15%, data not shown).
GT induces apoptosis in monocyte-derived dendritic cells.
Our previous experiments demonstrated that GT , we sought to determine whether monocyte-derived DC were similarly susceptible to apoptosis induction by GT. To test this hypothesis, we isolated monocytes from PBMC via adherence, and then induced them to differentiate into immature and then mature DC. We then assessed the induction of apoptosis in monocyte-derived DC using caspase-3 induction as an endpoint following sequential gating on DC by scatter and CD83 expression (Fig. 7) . Results were similar to those obtained using peripheral blood monocytes, with marked induction of apoptosis in CD83+ DC in the presence of GT. Furthermore, our results suggest that GT inhibits antigen presentation and induces the preferential death of monocytes via an apoptotic mechanism, and that apoptosis was similarly induced in monocyte-derived CD83+ DC. These results suggest a novel and potentially clinically significant means by which AF may subvert a protective human cellular immune response.
Our results, using a CFC approach to detect AF-specific T cell responses, differ from those of Hebart, et al., who described the presence of detectable proliferative responses using a similar AF-derived antigen preparation in the majority of donors examined. Hebart, et al., also evaluated cytokine levels in cell-free supernatants after PBMC stimulation, whereas we evaluated cytokine production at the single-cell level by flow cytometry 12 . It is possible that the approach we utilized here is less sensitive, though our prior studies and those of others have validated the use of CFC-based assays as an accurate and clinically meaningful way to detect the frequencies of human T cells recognizing CMV, HIV and other relevant pathogens 25, 26, [30] [31] [32] [33] . It is also conceivable that patient-related variables or differences in the antigenicity of the AF strains used in our respective studies were responsible for the differences observed.
Prior studies have suggested that GT may inhibit T cell activation via disruption of the NF-κB pathway. Additionally, inhibition of NF-κB activation increases apoptotic death in different cell types 20, [34] [35] [36] . In concordance with this relationship, GT has been found to cause 15, [36] [37] [38] [39] [40] [41] . In vivo experiments have demonstrated the ability of GT to induce apoptosis in thymus, spleen, mesenteric nodes and liver 42 .
However, the induction of apoptosis in human monocytes has not previously been suggested as a potential by which AF may suppress and evade the protective human immune response.
As an ETP compound, GT acts as a redox active toxin and has been shown to form mixed disulfides with accessible thiol residues on proteins 43 . The inhibition of NF-κB could be caused by the interaction of GT with an essential thiol 20 . Reduced GT has been specifically identified in cells following exposure to the toxin 16 . The intracellular production of superoxide, hydrogen peroxide and, finally, hydroxide radical reactive oxygen species during the GT redox cycle could directly damage cellular DNA leading to a pro-apoptotic signaling cascade 44 . Recently, Bernardo et al. 45 demonstrated that uptake and the subsequent cell killing by GT is dependent on intracellular glutathione, which is needed to actively concentrate the reduced dithiol form in the cell. Using glutathione depletors, such as diethyl maleate and diamide, it was possible to disrupt GT uptake 45 . What is not known is whether agents with similar activity might be used to prevent GT uptake in human subjects, perhaps inhibiting the toxic effects of GT production locally.
Our results may have important implications for potential diagnostic and therapeutic strategies aimed at improving outcomes in human IA. The demonstration that GT-induced T cell suppression and monocyte apoptosis occurs at concentrations below those recently reported in human clinical subjects 24 supports the possibility that gliotoxin levels might serve as a useful sentinel marker of disease progression or be associated with poor prognosis in IA.
Further clinical studies will be necessary to address this hypothesis, and to determine whether the extent of gliotoxin production by a given AF strain might influence pathogenicity and the likelihood of progression to IA in vivo. It is also important to note that other substances secreted by AF, in addition to or instead of gliotoxin, may have mediated the effects we observed due to crude filtrates. Additional studies to fractionate AF lysates could definitively Prior studies have demonstrated a close association between CMV reactivation, CMV disease and IA 6, 7 . It is possible that this association is simply due to the poor underlying state of the immune system in susceptible patients and the direct effects of immunsuppressive therapy for GVHD on the reactivation of both infections. However, our results suggest a model wherein early IA may result in the local elaboration of GT which leads to the demise of APC and their compromise, with additional direct and indirect effects on T cells known to be important in controlling CMV reactivation 25, 26 . Thus, GT production during the early stage of IA may directly increase the likelihood of local CMV reactivation, which may potentiate local tissue injury. Additional studies will be required to determine whether GT production at sites of early IA (e.g., in the lung) results in an increased propensity to reactivate CMV locally.
Given the importance of IA in the post-SCT setting, and the prior success of adoptive cellular therapies for other pathogens, including CMV and Epstein-Barr virus, vaccination and adoptive infusion of T cells has been contemplated as a method of prophylaxis or therapy for human IA. Our experiments suggest that the ability of APC to present AF antigens is likely to be markedly impaired in the presence of GT. Thus, efforts to expand T cells ex vivo would likely be benefited by the use of AF antigen preparations that contain little or no GT.
In conclusion, we have demonstrated that the production of GT by AF may constitute a novel immunsuppressive mechanism that results in the destruction and functional impairment of the APC arm of the cellular immune response. Further studies will be required to determine the importance of this putative mechanism in the clinical setting. Additional studies may facilitate the development of novel clinical approaches to circumvent or neutralize the effects of GT in vivo. Such studies have the potential to overcome our existing limitations in diagnosing, preventing and effectively treating AF infections in immunocompromised patients.
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